Virulence-targeted Antibacterials: Concept, Promise, and Susceptibility to Resistance Mechanisms

Chemical Biology and Drug Design

Volumn 86, Issue 4, 2015, Pages 379-399

  Ruer, Ségolène ^a   Pinotsis, Nikos ^c   Steadman, David ^d   Waksman, Gabriel ^c   Remaut, Han ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antibiotic resistance; bacterial virulence; drug discovery; mechanism based drug design; molecular recognition; therapeutic target

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL TOXIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BIOFILM; GENETIC VARIABILITY; IMMUNE EVASION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; QUORUM SENSING; REVIEW; UPREGULATION; BACTERIAL INFECTIONS; BACTERIUM; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL ADHESION; BACTERIAL INFECTIONS; BIOFILMS; DRUG RESISTANCE, BACTERIAL; HUMANS; QUORUM SENSING;

EID: 84942552168     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12517     Document Type: Review

References (218)

1. WHO. Antimicrobial resistance: global report on surveillance 2014. Available from: http://www.who.int/drugresistance/documents/surveillancereport/en/.
2. Clatworthy A.E., Pierson E., Hung D.T., (2007) Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol; 3: 541-548.
3. Davies J., Davies D., (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev; 74: 417-433.
4. Petty N.K., Ben Zakour N.L., Stanton-Cook M., Skippington E., Totsika M., Forde B.M., Phan M.D., et al., (2014) Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A; 111: 5694-5699.
5. Falcone M., Venditti M., Corrao S., Serra P., (2011) Role of multidrug-resistant pathogens in health-care-associated pneumonia. Lancet Infect Dis; 11: 11-12; author reply 2-3.
6. Abraham E.P., Chain E., (1940) An enzyme from bacteria able to destroy penicillin. Nature; 146: 837.
7. Morar M., Wright G.D., (2010) The genomic enzymology of antibiotic resistance. Annu Rev Genet; 44: 25-51.
8. Levy S.B., Marshall B., (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med; 10 (12 Suppl): S122-S129.
9. Levy S.B., (1998) Antimicrobial resistance: bacteria on the defence. Resistance stems from misguided efforts to try to sterilise our environment. BMJ; 317: 612-613.
10. Alekshun M.N., Levy S.B., (2007) Molecular mechanisms of antibacterial multidrug resistance. Cell; 128: 1037-1050.
11. Martinez J.L., (2009) The role of natural environments in the evolution of resistance traits in pathogenic bacteria. Proc Biol Sci; 276: 2521-2530.
12. Rasko D.A., Sperandio V., (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov; 9: 117-128.
13. Nathan C., (2012) Fresh approaches to anti-infective therapies. Sci Transl Med; 4: 13.
14. Cegelski L., Marshall G.R., Eldridge G.R., Hultgren S.J., (2008) The biology and future prospects of antivirulence therapies. Nat Rev Microbiol; 6: 17-27.
15. Waldor M.K., (2006) Disarming pathogens-a new approach for antibiotic development. N Engl J Med; 354: 296-297.
16. Cho I., Yamanishi S., Cox L., Methe B.A., Zavadil J., Li K., Gao Z., Mahana D., Raju K., Teitler I., Li H., Alekseyenko A.V., Blaser M.J., (2012) Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature; 488: 621-626.
17. Dethlefsen L., Huse S., Sogin M.L., Relman D.A., (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol; 6: e280.
18. Cusumano C.K., Pinkner J.S., Han Z., Greene S.E., Ford B.A., Crowley J.R., Henderson J.P., Janetka J.W., Hultgren S.J., (2011) Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med; 3: 109ra15.
19. Starkey M., Lepine F., Maura D., Bandyopadhaya A., Lesic B., He J., Kitao T., Righi V., Milot S., Tzika A., Rahme L., (2014) Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity. PLoS Pathog; 10: e1004321.
20. Martinez J.L., Baquero F., (2014) Emergence and spread of antibiotic resistance: setting a parameter space. Ups J Med Sci; 119: 68-77.
21. Andersson D.I., Hughes D., (2014) Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol; 12: 465-478.
22. Palmer A.C., Kishony R., (2013) Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. Nat Rev Genet; 14: 243-248.
23. Liu B., Pop M., (2009) ARDB-antibiotic resistance genes database. Nucleic Acids Res; 37 (Database issue): D443-D447.
24. Wright G.D., (2007) The antibiotic resistome: the nexus of chemical and genetic diversity. Nat Rev Microbiol; 5: 175-186.
25. Normark B.H., Normark S., (2002) Evolution and spread of antibiotic resistance. J Intern Med; 252: 91-106.
26. Harbottle H., Thakur S., Zhao S., White D.G., (2006) Genetics of antimicrobial resistance. Anim Biotechnol; 17: 111-124.
27. Yoon E.J., Kwon A.R., Min Y.H., Choi E.C., (2008) Foggy D-shaped zone of inhibition in Staphylococcus aureus owing to a dual character of both inducible and constitutive resistance to macrolide-lincosamide-streptogramin B. J Antimicrob Chemother; 61: 533-540.
28. Guilhelmelli F., Vilela N., Albuquerque P., Derengowski Lda S., Silva-Pereira I., Kyaw C.M., (2013) Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front Microbiol; 4: 353.
29. Saar-Dover R., Bitler A., Nezer R., Shmuel-Galia L., Firon A., Shimoni E., Trieu-Cuot P., Shai Y., (2012) D-alanylation of lipoteichoic acids confers resistance to cationic peptides in group B streptococcus by increasing the cell wall density. PLoS Pathog; 8: e1002891.
30. Bertsche U., Weidenmaier C., Kuehner D., Yang S.J., Baur S., Wanner S., Francois P., Schrenzel J., Yeaman M.R., Bayer A.S., (2011) Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation. Antimicrob Agents Chemother; 55: 3922-3928.
31. Disalvo E.A., Simon S.A., (1995) Permeability and stability of lipid bilayers. London, UK: CRC Press.
32. Forster B.M., Marquis H., (2012) Protein transport across the cell wall of monoderm Gram-positive bacteria. Mol Microbiol; 84: 405-413.
33. Green D.W., (2002) The bacterial cell wall as a source of antibacterial targets. Expert Opin Ther Targets; 6: 1-19.
34. Delcour A.H., (2009) Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta; 1794: 808-816.
35. Nikaido H., Vaara M., (1985) Molecular basis of bacterial outer membrane permeability. Microbiol Rev; 49: 1-32.
36. Wiener M.C., (2005) TonB-dependent outer membrane transport: going for Baroque? Curr Opin Struct Biol; 15: 394-400.
37. Gause G.F., (1955) Recent studies on albomycin, a new antibiotic. Br Med J; 2: 1177-1179.
38. Fiedler H.P., Walz F., Dohle A., Zahner H., (1985) Albomycin-studies on fermentation, isolation and quantitative-determination. Appl Microbiol Biotechnol; 21: 341-347.
39. Vertesy L., Aretz W., Fehlhaber H.W., Kogler H., (1995) Salmycin a-D, antibiotics from streptomyces-violaceus, Dsm-8286, having a siderophore aminoglycoside structure. Helv Chim Acta; 78: 46-60.
40. Ferguson A.D., Braun V., Fiedler H.P., Coulton J.W., Diederichs K., Welte W., (2000) Crystal structure of the antibiotic albomycin in complex with the outer membrane transporter FhuA. Protein Sci; 9: 956-963.
41. Ferguson A.D., Kodding J., Walker G., Bos C., Coulton J.W., Diederichs K., Braun V., Welte W., (2001) Active transport of an antibiotic rifamycin derivative by the outer-membrane protein FhuA. Structure; 9: 707-716.
42. Destoumieux-Garzon D., Duquesne S., Peduzzi J., Goulard C., Desmadril M., Letellier L., Rebuffat S., Boulanger P., (2005) The iron-siderophore transporter FhuA is the receptor for the antimicrobial peptide microcin J25: role of the microcin Val11-Pro16 beta-hairpin region in the recognition mechanism. Biochem J; 389 (Pt 3): 869-876.
43. Pramanik A., Braun V., (2006) Albomycin uptake via a ferric hydroxamate transport system of Streptococcus pneumoniae R6. J Bacteriol; 188: 3878-3886.
44. Mathavan I., Zirah S., Mehmood S., Choudhury H.G., Goulard C., Li Y., Robinson C.V., Rebuffat S., Beis K., (2014) Structural basis for hijacking siderophore receptors by antimicrobial lasso peptides. Nat Chem Biol; 10: 340-342.
45. Pugsley A.P., Zimmerman W., Wehrli W., (1987) Highly efficient uptake of a rifamycin derivative via the FhuA-TonB-dependent uptake route in Escherichia coli. J Gen Microbiol; 133: 3505-3511.
46. Gorska A., Sloderbach A., Marszall M.P., (2014) Siderophore-drug complexes: potential medicinal applications of the 'Trojan horse' strategy. Trends Pharmacol Sci; 35: 442-449.
47. Bleck C.K., Merz A., Gutierrez M.G., Walther P., Dubochet J., Zuber B., Griffiths G., (2010) Comparison of different methods for thin section EM analysis of Mycobacterium smegmatis. J Microsc; 237: 23-38.
48. Bansal-Mutalik R., Nikaido H., (2014) Mycobacterial outer membrane is a lipid bilayer and the inner membrane is unusually rich in diacyl phosphatidylinositol dimannosides. Proc Natl Acad Sci U S A; 111: 4958-4963.
49. Schwebach J.R., Glatman-Freedman A., Gunther-Cummins L., Dai Z., Robbins J.B., Schneerson R., Casadevall A., (2002) Glucan is a component of the Mycobacterium tuberculosis surface that is expressed in vitro and in vivo. Infect Immun; 70: 2566-2575.
50. Zuber B., Chami M., Houssin C., Dubochet J., Griffiths G., Daffe M., (2008) Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J Bacteriol; 190: 5672-5680.
51. Hoffmann C., Leis A., Niederweis M., Plitzko J.M., Engelhardt H., (2008) Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc Natl Acad Sci U S A; 105: 3963-3967.
52. Migliardo F., Salmeron C., Bayan N., (2014) Mobility and temperature resistance of trehalose mycolates as key characteristics of the outer membrane of Mycobacterium tuberculosis. J Biomol Struct Dyn; 33: 447-459.
53. Gebhardt H., Meniche X., Tropis M., Kramer R., Daffe M., Morbach S., (2007) The key role of the mycolic acid content in the functionality of the cell wall permeability barrier in Corynebacterineae. Microbiology; 153 (Pt 5): 1424-1434.
54. O'Toole G.A., Pratt L.A., Watnick P.I., Newman D.K., Weaver V.B., Kolter R., (1999) Genetic approaches to study of biofilms. Methods Enzymol; 310: 91-109.
55. Costerton J.W., (2001) Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol; 9: 50-52.
56. Hoffman L.R., D'Argenio D.A., MacCoss M.J., Zhang Z., Jones R.A., Miller S.I., (2005) Aminoglycoside antibiotics induce bacterial biofilm formation. Nature; 436: 1171-1175.
57. Karatan E., Watnick P., (2009) Signals, regulatory networks, and materials that build and break bacterial biofilms. Microbiol Mol Biol Rev; 73: 310-347.
58. Stewart P.S., Costerton J.W., (2001) Antibiotic resistance of bacteria in biofilms. Lancet; 358: 135-138.
59. Piddock L.J., (2006) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev; 19: 382-402.
60. Piddock L.J., (2006) Multidrug-resistance efflux pumps-not just for resistance. Nat Rev Microbiol; 4: 629-636.
61. Lubelski J., Konings W.N., Driessen A.J., (2007) Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev; 71: 463-476.
62. Martinez J.L., Sanchez M.B., Martinez-Solano L., Hernandez A., Garmendia L., Fajardo A., Alvarez-Ortega C., (2009) Functional role of bacterial multidrug efflux pumps in microbial natural ecosystems. FEMS Microbiol Rev; 33: 430-449.
63. Locher K.P., Lee A.T., Rees D.C., (2002) The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science; 296: 1091-1098.
64. McMurry L., Petrucci R.E. Jr, Levy S.B., (1980) Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc Natl Acad Sci U S A; 77: 3974-3977.
65. Chen H.Y., Yuan M., Livermore D.M., (1995) Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol; 43: 300-309.
66. Zimmermann W., Rosselet A., (1977) Function of outer membrane of Escherichia-coli as a permeability barrier to beta-lactam antibiotics. Antimicrob Agents Chemother; 12: 368-372.
67. Fukuda H., Hosaka M., Iyobe S., Gotoh N., Nishino T., Hirai K., (1995) nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother; 39: 790-792.
68. Manning A.J., Kuehn M.J., (2011) Contribution of bacterial outer membrane vesicles to innate bacterial defense. BMC Microbiol; 11: 258.
69. Fourmy D., Recht M.I., Blanchard S.C., Puglisi J.D., (1996) Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science; 274: 1367-1371.
70. Mingeot-Leclercq M.P., Glupczynski Y., Tulkens P.M., (1999) Aminoglycosides: activity and resistance. Antimicrob Agents Chemother; 43: 727-737.
71. Carter A.P., Clemons W.M., Brodersen D.E., Morgan-Warren R.J., Wimberly B.T., Ramakrishnan V., (2000) Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature; 407: 340-348.
72. Chopra I., (1985) The tetracyclines. In:, Hlavaka J.J., Boothe J.H., editors. Handbook of Experimental Pharmacology, 78. New York: Springer-Verlag; p. 317-392.
73. Brisson-Noel A., Trieu-Cuot P., Courvalin P., (1988) Mechanism of action of spiramycin and other macrolides. J Antimicrob Chemother; 22 (Suppl B): 13-23.
74. Wittmann H.G., Apirion D., (1975) Analysis of ribosomal proteins in streptomycin resistant and dependent mutants isolated from streptomycin independent Escherichia coli strains. Mol Gen Genet; 141: 331-341.
75. Finken M., Kirschner P., Meier A., Wrede A., Bottger E.C., (1993) Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol; 9: 1239-1246.
76. Springer B., Kidan Y.G., Prammananan T., Ellrott K., Bottger E.C., Sander P., (2001) Mechanisms of streptomycin resistance: selection of mutations in the 16S rRNA gene conferring resistance. Antimicrob Agents Chemother; 45: 2877-2884.
77. Chopra I., Roberts M., (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev; 65: 232-260; second page, table of contents.
78. Connell S.R., Tracz D.M., Nierhaus K.H., Taylor D.E., (2003) Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother; 47: 3675-3681.
79. Weisblum B., (1995) Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother; 39: 577-585.
80. Suzuki R.B., Lopes R.A., da Camara Lopes G.A., Hung Ho T., Speranca M.A., (2013) Low Helicobacter pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of Sao Paulo, Brazil. BMC Gastroenterol; 13: 164.
81. Takiff H.E., Salazar L., Guerrero C., Philipp W., Huang W.M., Kreiswirth B., Cole S.T., Jacobs W.R. Jr, Telenti A., (1994) Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother; 38: 773-780.
82. Hiasa H., Shea M.E., (2000) DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex. J Biol Chem; 275: 34780-34786.
83. Tran J.H., Jacoby G.A., (2002) Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A; 99: 5638-5642.
84. Tran J.H., Jacoby G.A., Hooper D.C., (2005) Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother; 49: 3050-3052.
85. Poirel L., Rodriguez-Martinez J.M., Mammeri H., Liard A., Nordmann P., (2005) Origin of plasmid-mediated quinolone resistance determinant QnrA. Antimicrob Agents Chemother; 49: 3523-3525.
86. Sanchez M.B., Hernandez A., Rodriguez-Martinez J.M., Martinez-Martinez L., Martinez J.L., (2008) Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of Qnr determinants. BMC Microbiol; 8: 148.
87. Hegde S.S., Vetting M.W., Roderick S.L., Mitchenall L.A., Maxwell A., Takiff H.E., Blanchard J.S., (2005) A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science; 308: 1480-1483.
88. Dryden D.T., Tock M.R., (2006) DNA mimicry by proteins. Biochem Soc Trans; 34 (Pt 2): 317-319.
89. Khrapunov S., Brenowitz M., (2011) Stability, denaturation and refolding of Mycobacterium tuberculosis MfpA, a DNA mimicking protein that confers antibiotic resistance. Biophys Chem; 159: 33-40.
90. Maxwell A., (1997) DNA gyrase as a drug target. Trends Microbiol; 5: 102-109.
91. Vetting M.W., Hegde S.S., Fajardo J.E., Fiser A., Roderick S.L., Takiff H.E., Blanchard J.S., (2006) Pentapeptide repeat proteins. Biochemistry; 45: 1-10.
92. Wang J.C., (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol; 3: 430-440.
93. Hooper D.C., (1995) Quinolone mode of action. Drugs; 49 (Suppl 2): 10-15.
94. Piddock L.J., (1995) Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs; 49 (Suppl 2): 29-35.
95. Yoshida H., Bogaki M., Nakamura M., Nakamura S., (1990) Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother; 34: 1271-1272.
96. Walsh C.T., Fisher S.L., Park I.S., Prahalad M., Wu Z., (1996) Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Chem Biol; 3: 21-28.
97. Fisher J.F., Meroueh S.O., Mobashery S., (2005) Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev; 105: 395-424.
98. Song M.D., Wachi M., Doi M., Ishino F., Matsuhashi M., (1987) Evolution of an inducible penicillin-target protein in methicillin-resistant Staphylococcus aureus by gene fusion. FEBS Lett; 221: 167-171.
99. Spratt B.G., (1994) Resistance to antibiotics mediated by target alterations. Science; 264: 388-393.
100. Bush K., Jacoby G.A., (2010) Updated functional classification of beta-lactamases. Antimicrob Agents Chemother; 54: 969-976.
101. Philippon A., Labia R., Jacoby G., (1989) Extended-spectrum beta-lactamases. Antimicrob Agents Chemother; 33: 1131-1136.
102. Walsh C., (2000) Molecular mechanisms that confer antibacterial drug resistance. Nature; 406: 775-781.
103. Shaw K.J., Rather P.N., Hare R.S., Miller G.H., (1993) Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev; 57: 138-163.
104. Livermore D.M., Woodford N., (2006) The beta-lactamase threat in Enterobacteriaceae. Pseudomonas and Acinetobacter. Trends Microbiol; 14: 413-420.
105. Bradford P.A., (2001) Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev; 14: 933-951, table of contents.
106. Dantas G., Sommer M.O., Oluwasegun R.D., Church G.M., (2008) Bacteria subsisting on antibiotics. Science; 320: 100-103.
107. Jacoby G.A., (2005) Mechanisms of resistance to quinolones. Clin Infect Dis; 41 (Suppl. 2): S120-S126.
108. Maia A.S., Ribeiro A.R., Amorim C.L., Barreiro J.C., Cass Q.B., Castro P.M., Tiritan M.E., (2014) Degradation of fluoroquinolone antibiotics and identification of metabolites/transformation products by liquid chromatography-tandem mass spectrometry. J Chromatogr A; 1333: 87-98.
109. Wetzstein H.G., Schmeer N., Karl W., (1997) Degradation of the fluoroquinolone enrofloxacin by the brown rot fungus Gloeophyllum striatum: identification of metabolites. Appl Environ Microbiol; 63: 4272-4281.
110. Mellbye B., Schuster M., (2011) The sociomicrobiology of antivirulence drug resistance: a proof of concept. MBio; 2: 4.
111. Miller M.B., Bassler B.L., (2001) Quorum sensing in bacteria. Annu Rev Microbiol; 55: 165-199.
112. Defoirdt T., Boon N., Bossier P., (2010) Can bacteria evolve resistance to quorum sensing disruption? PLoS Pathog; 6: e1000989.
113. Finch R.G., Pritchard D.I., Bycroft B.W., Williams P., Stewart G., (1998) Quorum sensing: a novel target for anti-infective therapy. J Antimicrob Chemother; 42: 569-571.
114. Kusari P., Kusari S., Lamshoft M., Sezgin S., Spiteller M., Kayser O., (2014) Quorum quenching is an antivirulence strategy employed by endophytic bacteria. Appl Microbiol Biotechnol; 98: 7173-7183.
115. Janssens J.C., De Keersmaecker S.C., De Vos D.E., Vanderleyden J., (2008) Small molecules for interference with cell-cell-communication systems in Gram-negative bacteria. Curr Med Chem; 15: 2144-2156.
116. Smith D., Wang J.-H., Swatton J.E., Davenport P., Price B., Mikkelsen H., Stickland H., Nishikawa K., Gardiol N., Spring D.R., Welch M., (2006) Variations on a theme: diverse N-acyl homoserine lactone-mediated quorum sensing mechanisms in Gram-negative bacteria. Sci Prog; 89 (Part 3-4): 167-211.
117. Jiang T., Li M., (2013) Quorum sensing inhibitors: a patent review. Expert Opin Ther Pat; 23: 867-894.
118. Bhardwaj A.K., Vinothkumar K., Rajpara N., (2013) Bacterial quorum sensing inhibitors: attractive alternatives for control of infectious pathogens showing multiple drug resistance. Recent Pat Antiinfect Drug Discov; 8: 68-83.
119. Pan J., Ren D., (2009) Quorum sensing inhibitors: a patent overview. Expert Opin Ther Pat; 19: 1581-1601.
120. More M.I., Finger L.D., Stryker J.L., Fuqua C., Eberhard A., Winans S.C., (1996) Enzymatic synthesis of a quorum-sensing autoinducer through use of defined substrates. Science; 272: 1655-1658.
121. Gutierrez J.A., Crowder T., Rinaldo-Matthis A., Ho M.-C., Almo S.C., Schramm V.L., (2009) Transition state analogs of 5 '-methylthioadenosine nucleosidase disrupt quorum sensing. Nat Chem Biol; 5: 251-257.
122. Givskov M., DeNys R., Manefield M., Gram L., Maximilien R., Eberl L., Molin S., Steinberg P.D., Kjelleberg S., (1996) Eukaryotic interference with homoserine lactone-mediated prokaryotic signaling. J Bacteriol; 178: 6618-6622.
123. Ren D., Sims J.J., Wood T.K., (2001) Inhibition of biofilm formation and swarming of Escherichia coli by (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone. Environ Microbiol; 3: 731-736.
124. Lowery C.A., Dickerson T.J., Janda K.D., (2008) Interspecies and interkingdom communication mediated by bacterial quorum sensing. Chem Soc Rev; 37: 1337-1346.
125. Lowery C.A., Salzameda N.T., Sawada D., Kaufmann G.F., Janda K.D., (2010) Medicinal chemistry as a conduit for the modulation of Quorum sensing. J Med Chem; 53: 7467-7489.
126. Kline T., Bowman J., Iglewski B.H., de Kievit T., Kakai Y., Passador L., (1999) Novel synthetic analogs of the Pseudomonas autoinducer. Bioorg Med Chem Lett; 9: 3447-3452.
127. Chen G., Swem L.R., Swem D.L., Stauff D.L., O'Loughlin C.T., Jeffrey P.D., Bassler B.L., Hughson F.M., (2011) A strategy for antagonizing quorum sensing. Mol Cell; 42: 199-209.
128. Geske G.D., O'Neill J.C., Miller D.M., Wezeman R.J., Mattmann M.E., Lin Q., Blackwell H.E., (2008) Comparative analyses of N-Acylated homoserine lactones reveal unique structural features that dictate their ability to activate or inhibit quorum sensing. ChemBioChem; 9: 389-400.
129. McInnis C.E., Blackwell H.E., (2014) Non-native N-aroyl L-homoserine lactones are potent modulators of the quorum sensing receptor RpaR in Rhodopseudomonas palustris. ChemBioChem; 15: 87-93.
130. Stacy A.E., Jansson P.J., Richardson D.R., (2013) Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol; 84: 655-669.
131. Stacy D.M., Welsh M.A., Rather P.N., Blackwell H.E., (2012) Attenuation of quorum sensing in the pathogen Acinetobacter baumannii using non-native N-Acyl homoserine lactones. ACS Chem Biol; 7: 1719-1728.
132. O'Loughlin C.T., Miller L.C., Siryaporn A., Drescher K., Semmelhack M.F., Bassler B.L., (2013) A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc Natl Acad Sci U S A; 110: 17981-17986.
133. Ganguly K., Wu R., Ollivault-Shiflett M., Goodwin P.M., Silks L.A. III, Iyer R., (2011) Design, synthesis, and a novel application of quorum-sensing agonists as potential drug-delivery vehicles. J Drug Target; 19: 528-539.
134. Maeda T., Garcia-Contreras R., Pu M., Sheng L., Garcia L.R., Tomas M., Wood T.K., (2012) Quorum quenching quandary: resistance to antivirulence compounds. ISME J; 6: 493-501.
135. Allen R.C., Popat R., Diggle S.P., Brown S.P., (2014) Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol; 12: 300-308.
136. Brader G., Sjöblom S., Hyytiäinen H., Sims-Huopaniemi K., Palva E.T., (2005) Altering substrate chain length specificity of an acylhomoserine lactone synthase in bacterial communication. J Biol Chem; 280: 10403-10409.
137. Case R.J., Labbate M., Kjelleberg S., (2008) AHL-driven quorum-sensing circuits: their frequency and function among the Proteobacteria. ISME J; 2: 345-349.
138. Hentzer M., Wu H., Andersen J.B., Riedel K., Rasmussen T.B., Bagge N., Kumar N., et al., (2003) Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J; 22: 3803-3815.
139. Swem L.R., Swem D.L., O'Loughlin C.T., Gatmaitan R., Zhao B., Ulrich S.M., Bassler B.L., (2009) A quorum-sensing antagonist targets both membrane-bound and cytoplasmic receptors and controls bacterial pathogenicity. Mol Cell; 35: 143-153.
140. Wilder C.N., Diggle S.P., Schuster M., (2011) Cooperation and cheating in Pseudomonas aeruginosa: the roles of the las, rhl and pqs quorum-sensing systems. ISME J; 5: 1332-1343.
141. Gerdt J.P., Blackwell H.E., (2014) Competition studies confirm two major barriers that can preclude the spread of resistance to quorum-sensing inhibitors in bacteria. ACS Chem Biol; 9: 2291-2299.
142. Lo A.W.H., Van de Water K., Gane P.J., Chan A.W.E., Steadman D., Stevens K., Selwood D.L., Waksman G., Remaut H., (2014) Suppression of type 1 pilus assembly in uropathogenic Escherichia coli by chemical inhibition of subunit polymerization. J Antimicrob Chemother; 69: 1017-1026.
143. Chorell E., Pinkner J.S., Bengtsson C., Banchelin T.S., Edvinsson S., Linusson A., Hultgren S.J., Almqvist F., (2012) Mapping pilicide anti-virulence effect in Escherichia coli, a comprehensive structure-activity study. Bioorg Med Chem; 20: 3128-3142.
144. Lo A.W.H., Moonens K., Remaut H., (2013) Chemical attenuation of pilus function and assembly in Gram-negative bacteria. Curr Opin Microbiol; 16: 85-92.
145. Lee Y.M., Almqvist F., Hultgren S.J., (2003) Targeting virulence for antimicrobial chemotherapy. Curr Opin Pharmacol; 3: 513-519.
146. Geibel S., Waksman G., (2014) The molecular dissection of the chaperone-usher pathway. Biochim Biophys Acta; 1843: 1559-1567.
147. Anderson G.G., Palermo J.J., Schilling J.D., Roth R., Heuser J., Hultgren S.J., (2003) Intracellular bacterial biofilm-like pods in urinary tract infections. Science; 301: 105-107.
148. Mulvey M.A., Lopez-Boado Y.S., Wilson C.L., Roth R., Parks W.C., Heuser J., Hultgren S.J., (1998) Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science; 282: 1494-1497.
149. Kuehn M.J., Heuser J., Normark S., Hultgren S.J., (1992) P pili in uropathogenic E. coli are composite fibres with distinct fibrillar adhesive tips. Nature; 356: 252-255.
150. Dodson K.W., Jacob-Dubuisson F., Striker R.T., Hultgren S.J., (1993) Outer-membrane PapC molecular usher discriminately recognizes periplasmic chaperone-pilus subunit complexes. Proc Natl Acad Sci U S A; 90: 3670-3674.
151. Phan G., Remaut H., Wang T., Allen W.J., Pirker K.F., Lebedev A., Henderson N.S., et al., (2011) Crystal structure of the FimD usher bound to its cognate FimC-FimH substrate. Nature; 474: 49-53.
152. Sauer F.G., Futterer K., Pinkner J.S., Dodson K.W., Hultgren S.J., Waksman G., (1999) Structural basis of chaperone function and pilus biogenesis. Science; 285: 1058-1061.
153. Sauer F.G., Pinkner J.S., Waksman G., Hultgren S.J., (2002) Chaperone priming of pilus subunits facilitates a topological transition that drives fiber formation. Cell; 111: 543-551.
154. Pinkner J.S., Remaut H., Buelens F., Miller E., Aberg V., Pemberton N., Hedenstrom M., Larsson A., Seed P., Waksman G., Hultgren S.J., Almqvist F., (2006) Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci U S A; 103: 17897-17902.
155. Larsson A., Johansson S.M., Pinkner J.S., Hultgren S.J., Almqvist F., Kihlberg J., Linusson A., (2005) Multivariate design, synthesis, and biological evaluation of peptide inhibitors of FimC/FimH protein-protein interactions in uropathogenic Escherichia coli. J Med Chem; 48: 935-945.
156. Chorell E., Pinkner J.S., Phan G., Edvinsson S., Buelens F., Remaut H., Waksman G., Hultgren S.J., Almqvist F., (2010) Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity. J Med Chem; 53: 5690-5695.
157. Han Z., Pinkner J.S., Ford B., Chorell E., Crowley J.M., Cusumano C.K., Campbell S., Henderson J.P., Hultgren S.J., Janetka J.W., (2012) Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem; 55: 3945-3959.
158. Schwardt O., Rabbani S., Hartmann M., Abgottspon D., Wittwer M., Kleeb S., Zalewski A., Smiesko M., Cutting B., Ernst B., (2011) Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Bioorg Med Chem; 19: 6454-6473.
159. Dang H.T., Chorell E., Uvell H., Pinkner J.S., Hultgren S.J., Almqvist F., (2014) Syntheses and biological evaluation of 2-amino-3-acyl-tetrahydrobenzothiophene derivatives; antibacterial agents with antivirulence activity. Org Biomol Chem; 12: 1942-1956.
160. Salminen A., Loimaranta V., Joosten J.A., Khan A.S., Hacker J., Pieters R.J., Finne J., (2007) Inhibition of P-fimbriated Escherichia coli adhesion by multivalent galabiose derivatives studied by a live-bacteria application of surface plasmon resonance. J Antimicrob Chemother; 60: 495-501.
161. Le Trong I., Aprikian P., Kidd B.A., Forero-Shelton M., Tchesnokova V., Rajagopal P., Rodriguez V., Interlandi G., Klevit R., Vogel V., Stenkamp R.E., Sokurenko E.V., Thomas W.E., (2010) Structural basis for mechanical force regulation of the adhesin FimH via finger trap-like beta sheet twisting. Cell; 141: 645-655.
162. Nilsson A.I., Zorzet A., Kanth A., Dahlstrom S., Berg O.G., Andersson D.I., (2006) Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc Natl Acad Sci U S A; 103: 6976-6981.
163. Poole K., (2005) Efflux-mediated antimicrobial resistance. J Antimicrob Chemother; 56: 20-51.
164. Yu E.W., Aires J.R., McDermott G., Nikaido H., (2005) A periplasmic drug-binding site of the AcrB multidrug efflux pump: a crystallographic and site-directed mutagenesis study. J Bacteriol; 187: 6804-6815.
165. Pos K.M., (2009) Drug transport mechanism of the AcrB efflux pump. Biochim Biophys Acta; 1794: 782-793.
166. Nikaido H., Basina M., Nguyen V., Rosenberg E.Y., (1998) Multidrug efflux pump AcrAB of Salmonella typhimurium excretes only those beta-lactam antibiotics containing lipophilic side chains. J Bacteriol; 180: 4686-4692.
167. Li X.Z., Ma D., Livermore D.M., Nikaido H., (1994) Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrob Agents Chemother; 38: 1742-1752.
168. Liu A., Fong A., Becket E., Yuan J., Tamae C., Medrano L., Maiz M., Wahba C., Lee C., Lee K., Tran K.P., Yang H., Hoffman R.M., Salih A., Miller J.H., (2011) Selective advantage of resistant strains at trace levels of antibiotics: a simple and ultrasensitive color test for detection of antibiotics and genotoxic agents. Antimicrob Agents Chemother; 55: 1204-1210.
169. Andersson D.I., Hughes D., (2011) Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol Rev; 35: 901-911.
170. Chassaing B., Rolhion N., de Vallee A., Salim S.Y., Prorok-Hamon M., Neut C., Campbell B.J., Soderholm J.D., Hugot J.P., Colombel J.F., Darfeuille-Michaud A., (2011) Crohn disease-associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J Clin Invest; 121: 966-975.
171. Pusz P., Bok E., Mazurek J., Stosik M., Baldy-Chudzik K., (2014) Type 1 fimbriae in commensal Escherichia coli derived from healthy humans. Acta Biochim Pol; 61: 389-392.
172. Connell H., Agace W., Hedlund M., Klemm P., Shembri M., Svanborg C., (1996) Fimbriae-mediated adherence induces mucosal inflammation and bacterial clearance. Consequences for anti-adhesion therapy. Adv Exp Med Biol; 408: 73-80.
173. Ashkar A.A., Mossman K.L., Coombes B.K., Gyles C.L., Mackenzie R., (2008) FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling. PLoS Pathog; 4: e1000233.
174. Kamada N., Kim Y.G., Sham H.P., Vallance B.A., Puente J.L., Martens E.C., Nunez G., (2012) Regulated virulence controls the ability of a pathogen to compete with the gut microbiota. Science; 336: 1325-1329.
175. Kamada N., Chen G.Y., Inohara N., Nunez G., (2013) Control of pathogens and pathobionts by the gut microbiota. Nat Immunol; 14: 685-690.
176. Bjorkman J., Nagaev I., Berg O.G., Hughes D., Andersson D.I., (2000) Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science; 287: 1479-1482.
177. Gillespie S.H., Billington O.J., Breathnach A., McHugh T.D., (2002) Multiple drug-resistant Mycobacterium tuberculosis: evidence for changing fitness following passage through human hosts. Microb Drug Resist; 8: 273-279.
178. Felise H.B., Nguyen H.V., Pfuetzner R.A., Barry K.C., Jackson S.R., Blanc M.P., Bronstein P.A., Kline T., Miller S.I., (2008) An inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe; 4: 325-336.
179. Steadman D., Lo A., Waksman G., Remaut H., (2014) Bacterial surface appendages as targets for novel antibacterial therapeutics. Future Microbiol; 9: 887-900.
180. Cegelski L., Pinkner J.S., Hammer N.D., Cusumano C.K., Hung C.S., Chorell E., Aberg V., Walker J.N., Seed P.C., Almqvist F., Chapman M.R., Hultgren S.J., (2009) Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol; 5: 913-919.
181. Andersson E.K., Bengtsson C., Evans M.L., Chorell E., Sellstedt M., Lindgren A.E., Hufnagel D.A., Bhattacharya M., Tessier P.M., Wittung-Stafshede P., Almqvist F., Chapman M.R., (2013) Modulation of curli assembly and pellicle biofilm formation by chemical and protein chaperones. Chem Biol; 20: 1245-1254.
182. Horvath I., Weise C.F., Andersson E.K., Chorell E., Sellstedt M., Bengtsson C., Olofsson A., Hultgren S.J., Chapman M., Wolf-Watz M., Almqvist F., Wittung-Stafshede P., (2012) Mechanisms of protein oligomerization: inhibitor of functional amyloids templates alpha-synuclein fibrillation. J Am Chem Soc; 134: 3439-3444.
183. Arita-Morioka K.I., Yamanaka K., Mizunoe Y., Ogura T., Sugimoto S., (2015) A novel strategy for biofilm inhibition by using small molecules targeting molecular chaperone DnaK. Antimicrob Agents Chemother; 59: 633-641.
184. Baugh S., Phillips C.R., Ekanayaka A.S., Piddock L.J., Webber M.A., (2014) Inhibition of multidrug efflux as a strategy to prevent biofilm formation. J Antimicrob Chemother; 69: 673-681.
185. Baugh S., Ekanayaka A.S., Piddock L.J., Webber M.A., (2012) Loss of or inhibition of all multidrug resistance efflux pumps of Salmonella enterica serovar Typhimurium results in impaired ability to form a biofilm. J Antimicrob Chemother; 67: 2409-2417.
186. Kong L., Harrington L., Li Q., Cheley S., Davis B.G., Bayley H., (2013) Single-molecule interrogation of a bacterial sugar transporter allows the discovery of an extracellular inhibitor. Nat Chem; 5: 651-659.
187. Kaplan J.B., (2010) Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. J Dent Res; 89: 205-218.
188. Otsuka R., Imai S., Murata T., Nomura Y., Okamoto M., Tsumori H., Kakuta E., Hanada N., Momoi Y., (2015) Application of chimeric glucanase comprising mutanase and dextranase for prevention of dental biofilm formation. Microbiol Immunol; 59: 28-36.
189. Blackledge M.S., Worthington R.J., Melander C., (2013) Biologically inspired strategies for combating bacterial biofilms. Curr Opin Pharmacol; 13: 699-706.
190. Darouiche R.O., Mansouri M.D., Gawande P.V., Madhyastha S., (2009) Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination. J Antimicrob Chemother; 64: 88-93.
191. Bayer A.S., Park S., Ramos M.C., Nast C.C., Eftekhar F., Schiller N.L., (1992) Effects of alginase on the natural history and antibiotic therapy of experimental endocarditis caused by mucoid Pseudomonas aeruginosa. Infect Immun; 60: 3979-3985.
192. Lee J.H., Lee J., (2010) Indole as an intercellular signal in microbial communities. FEMS Microbiol Rev; 34: 426-444.
193. Furlani R.E., Yeagley A.A., Melander C., (2013) A flexible approach to 1,4-di-substituted 2-aminoimidazoles that inhibit and disperse biofilms and potentiate the effects of beta-lactams against multi-drug resistant bacteria. Eur J Med Chem; 62: 59-70.
194. Minvielle M.J., Bunders C.A., Melander C., (2013) Indole/triazole conjugates are selective inhibitors and inducers of bacterial biofilms. Medchemcomm; 4: 916-919.
195. Ackart D.F., Lindsey E.A., Podell B.K., Melander R.J., Basaraba R.J., Melander C., (2014) Reversal of Mycobacterium tuberculosis phenotypic drug resistance by 2-aminoimidazole-based small molecules. Pathog Dis; 70: 370-378.
196. Wright C.J., Wu H., Melander R.J., Melander C., Lamont R.J., (2014) Disruption of heterotypic community development by Porphyromonas gingivalis with small molecule inhibitors. Mol Oral Microbiol; 29: 185-193.
197. Stowe S.D., Thompson R.J., Peng L., Su Z., Blackledge M., Draughn G.L., Coe W.H., Johannes E., Lapham V.K., Mackenzie J., Melander C., Cavanagh J., (2015) Membrane- permeabilizing activity of reverse- amide 2- aminoimidazole antibiofilm agents against Acinetobacter Baumannii. Curr Drug Deliv. [Epub ahead of print].
198. Peng L., DeSousa J., Su Z., Novak B.M., Nevzorov A.A., Garland E.R., Melander C., (2011) Inhibition of Acinetobacter baumannii biofilm formation on a methacrylate polymer containing a 2-aminoimidazole subunit. Chem Commun (Camb); 47: 4896-4898.
199. Richards J.J., Reed C.S., Melander C., (2008) Effects of N-pyrrole substitution on the anti-biofilm activities of oroidin derivatives against Acinetobacter baumannii. Bioorg Med Chem Lett; 18: 4325-4327.
200. Bunders C.A., Richards J.J., Melander C., (2010) Identification of aryl 2-aminoimidazoles as biofilm inhibitors in Gram-negative bacteria. Bioorg Med Chem Lett; 20: 3797-3800.
201. Huigens R.W. 3rd, Rogers S.A., Steinhauer A.T., Melander C., (2009) Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem; 7: 794-802.
202. Yeagley A.A., Su Z., McCullough K.D., Worthington R.J., Melander C., (2013) N-substituted 2-aminoimidazole inhibitors of MRSA biofilm formation accessed through direct 1,3-bis(tert-butoxycarbonyl)guanidine cyclization. Org Biomol Chem; 11: 130-137.
203. Worthington R.J., Blackledge M.S., Melander C., (2013) Small-molecule inhibition of bacterial two-component systems to combat antibiotic resistance and virulence. Future Med Chem; 5: 1265-1284.
204. Harris T.L., Worthington R.J., Hittle L.E., Zurawski D.V., Ernst R.K., Melander C., (2014) Small molecule downregulation of PmrAB reverses lipid A modification and breaks colistin resistance. ACS Chem Biol; 9: 122-127.
205. Kim J., Park W., (2013) Indole inhibits bacterial quorum sensing signal transmission by interfering with quorum sensing regulator folding. Microbiology; 159 (Pt 12): 2616-2625.
206. Thompson R.J., Bobay B.G., Stowe S.D., Olson A.L., Peng L., Su Z., Actis L.A., Melander C., Cavanagh J., (2012) Identification of BfmR, a response regulator involved in biofilm development, as a target for a 2-Aminoimidazole-based antibiofilm agent. Biochemistry; 51: 9776-9778.
207. Yang L., Liu Y., Wu H., Song Z., Hoiby N., Molin S., Givskov M., (2012) Combating biofilms. FEMS Immunol Med Microbiol; 65: 146-157.
208. Bjarnsholt T., Ciofu O., Molin S., Givskov M., Hoiby N., (2013) Applying insights from biofilm biology to drug development-can a new approach be developed? Nat Rev Drug Discovery; 12: 791-808.
209. Alouf J.E., Popoff M.R., (2006) The comprehensive sourcebook of bacterial protein toxins. 3rd edn. Amsterdam; London: Elsevier Academic Press;. xxiii, 1047 pp.
210. Simon N.C., Aktories K., Barbieri J.T., (2014) Novel bacterial ADP-ribosylating toxins: structure and function. Nat Rev Microbiol; 12: 599-611.
211. Gandon S., Mackinnon M.J., Nee S., Read A.F., (2001) Imperfect vaccines and the evolution of pathogen virulence. Nature; 414: 751-756.
212. Soubeyrand B., Plotkin S.A., (2002) Microbial evolution: antitoxin vaccines and pathogen virulence. Nature; 417: 609-610; discussion 10.
213. Mooi F.R., Van Der Maas N.A., De Melker H.E., (2014) Pertussis resurgence: waning immunity and pathogen adaptation-two sides of the same coin. Epidemiol Infect; 142: 685-694.
214. Jacobson J.M., Yin J., Kitov P.I., Mulvey G., Griener T.P., James M.N., Armstrong G., Bundle D.R., (2014) The crystal structure of shiga toxin type 2 with bound disaccharide guides the design of a heterobifunctional toxin inhibitor. J Biol Chem; 289: 885-894.
215. Matias V.R., Beveridge T.J., (2006) Native cell wall organization shown by cryo-electron microscopy confirms the existence of a periplasmic space in Staphylococcus aureus. J Bacteriol; 188: 1011-1021.
216. Beveridge T.J., (1999) Structures of gram-negative cell walls and their derived membrane vesicles. J Bacteriol; 181: 4725-4733.
217. Ryjenkov D.A., Tarutina M., Moskvin O.V., Gomelsky M., (2005) Cyclic diguanylate is a ubiquitous signaling molecule in bacteria: insights into biochemistry of the GGDEF protein domain. J Bacteriol; 187: 1792-1798.
218. Antoniani D., Bocci P., Maciag A., Raffaelli N., Landini P., (2010) Monitoring of diguanylate cyclase activity and of cyclic-di-GMP biosynthesis by whole-cell assays suitable for high-throughput screening of biofilm inhibitors. Appl Microbiol Biotechnol; 85: 1095-1104.